27 related articles for article (PubMed ID: 38530254)
1. Atezolizumab/bevacizumab or lenvatinib in hepatocellular carcinoma: Multicenter real-world study with focus on bleeding and thromboembolic events.
Ben Khaled N; Möller M; Jochheim LS; Leyh C; Ehmer U; Böttcher K; Pinter M; Balcar L; Scheiner B; Weich A; Leicht HB; Zarka V; Ye L; Schneider J; Piseddu I; Öcal O; Rau M; Sinner F; Venerito M; Gairing SJ; Förster F; Mayerle J; De Toni EN; Geier A; Reiter FP
JHEP Rep; 2024 Jun; 6(6):101065. PubMed ID: 38798717
[TBL] [Abstract][Full Text] [Related]
2. Safety and Feasibility of Combining On-Demand Selective Locoregional Treatment with First-Line Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma.
Nakabori T; Higashi S; Abe Y; Mukai K; Ikawa T; Konishi K; Maeda N; Nakanishi K; Hasegawa S; Wada H; Ohkawa K
Curr Oncol; 2024 Mar; 31(3):1543-1555. PubMed ID: 38534950
[TBL] [Abstract][Full Text] [Related]
3. Feasibility of atezolizumab and bevacizumab combination regimens in patients with hepatocellular carcinoma and lung cancer taking direct oral anticoagulants.
Nakabori T; Kunimasa K; Kawabata M; Higashi S; Mukai K; Kawamura T; Inoue T; Tamiya M; Nishino K; Ohkawa K
Cancer Med; 2024 Jun; 13(12):e7430. PubMed ID: 38924675
[TBL] [Abstract][Full Text] [Related]
4. Distinct Characteristics and Changes in Liver Function of Patients with Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab for more than 1 Year.
Kim Y; Kim JS; Kang B; Kim I; Kim H; Lee WS; Sang YB; Jung S; An C; Kim C; Chon HJ
Cancer Res Treat; 2024 May; ():. PubMed ID: 38810969
[TBL] [Abstract][Full Text] [Related]
5. Downstaging with Atezolizumab-Bevacizumab: A Case Series.
Kulkarni AV; P K; Menon B; Sekaran A; Rambhatl A; Iyengar S; Alla M; Venishetty S; Ramachandra SK; V PG; Sharma M; Rao PN; Reddy DN; Singal AG
J Liver Cancer; 2024 May; ():. PubMed ID: 38797993
[TBL] [Abstract][Full Text] [Related]
6. Serum interleukin-6 levels at the start of the second course of atezolizumab plus bevacizumab therapy predict therapeutic efficacy in patients with advanced hepatocellular carcinoma: a multicenter analysis.
Suzuki T; Matsuura K; Suzuki Y; Okumura F; Nagura Y; Sobue S; Matoya S; Miyaki T; Kimura Y; Kusakabe A; Narahara S; Tokunaga T; Nagaoka K; Murakami S; Inoue T; Kuroyanagi K; Kawamura H; Fujiwara K; Nojiri S; Kataoka H; Tanaka Y
J Gastroenterol Hepatol; 2024 Jun; ():. PubMed ID: 38943340
[TBL] [Abstract][Full Text] [Related]
7. Proton Beam Therapy for Treating Patients with Hepatocellular Carcinoma with Major Portal Vein Tumor Invasion: A Single Center Retrospective Study.
Ishida T; Mizumoto M; Saito T; Okumura T; Miura K; Makishima H; Iizumi T; Numajiri H; Baba K; Murakami M; Nakamura M; Nakai K; Sakurai H
Cancers (Basel); 2024 May; 16(11):. PubMed ID: 38893169
[TBL] [Abstract][Full Text] [Related]
8. Safety/efficacy of atezolizumab + bevacizumab during anti-platelet/anticoagulation therapy in unresectable hepatocellular carcinoma.
Moriguchi M; Okuda K; Horiguchi G; Kataoka S; Seko Y; Yamaguchi K; Nishimura T; Fujii H; Mitsumoto Y; Miyagawa M; Kirishima T; Okishio S; Hara T; Ishikawa H; Nagao Y; Jo M; Ishii M; Tanaka S; Yamauchi N; Mitsuyoshi H; Nakajima T; Taketani H; Yano K; Arai M; Umemura A; Itoh Y
Liver Int; 2024 Jun; ():. PubMed ID: 38838097
[TBL] [Abstract][Full Text] [Related]
9. Correction: 'Efficacy and safety of radiotherapy combined with atezolizumab plus bevacizumab in treating hepatocellular carcinoma with portal vein tumour thrombus: a study protocol'.
BMJ Open; 2024 Jun; 14(6):e064688corr1. PubMed ID: 38904145
[No Abstract] [Full Text] [Related]
10. Prognosis and treatment pattern of advanced hepatocellular carcinoma after failure of first-line atezolizumab and bevacizumab treatment.
Chen CT; Feng YH; Yen CJ; Chen SC; Lin YT; Lu LC; Hsu CH; Cheng AL; Shao YY
Hepatol Int; 2022 Oct; 16(5):1199-1207. PubMed ID: 35986846
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
Liu J; Yang L; Wei S; Li J; Yi P
J Cancer Res Clin Oncol; 2023 Nov; 149(17):16191-16201. PubMed ID: 37658861
[TBL] [Abstract][Full Text] [Related]
12. Concurrent Atezolizumab Plus Bevacizumab and High-Dose External Beam Radiotherapy for Highly Advanced Hepatocellular Carcinoma.
Su CW; Teng W; Shen EY; Huang BS; Lin PT; Hou MM; Wu TH; Tsan DL; Hsieh CH; Wang CT; Chai PM; Lin CY; Lin SM; Lin CC
Oncologist; 2024 Mar; ():. PubMed ID: 38530254
[TBL] [Abstract][Full Text] [Related]
13. Intensity-modulated radiotherapy combined with systemic atezolizumab and bevacizumab in treatment of hepatocellular carcinoma with extrahepatic portal vein tumor thrombus: A preliminary multicenter single-arm prospective study.
Wang K; Xiang YJ; Yu HM; Cheng YQ; Liu ZH; Zhong JY; Feng S; Ni QZ; Zhu HF; Pan WW; Li JJ; Liang C; Zhou HK; Meng Y; Lau WY; Cheng SQ
Front Immunol; 2023; 14():1107542. PubMed ID: 36875125
[TBL] [Abstract][Full Text] [Related]
14. Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma.
Vithayathil M; D'Alessio A; Fulgenzi CAM; Nishida N; Schönlein M; von Felden J; Schulze K; Wege H; Saeed A; Wietharn B; Hildebrand H; Wu L; Ang C; Marron TU; Weinmann A; Galle PR; Bettinger D; Bengsch B; Vogel A; Balcar L; Scheiner B; Lee PC; Huang YH; Amara S; Muzaffar M; Naqash AR; Cammarota A; Zanuso V; Pressiani T; Pinter M; Cortellini A; Kudo M; Rimassa L; Pinato DJ; Sharma R
Hepatol Int; 2023 Aug; 17(4):904-914. PubMed ID: 37005953
[TBL] [Abstract][Full Text] [Related]
15. Transarterial Chemoembolization Combined with Atezolizumab Plus Bevacizumab or Lenvatinib for Unresectable Hepatocellular Carcinoma: A Propensity Score Matched Study.
Zhao C; Xiang Z; Li M; Wang H; Liu H; Yan H; Huang M
J Hepatocell Carcinoma; 2023; 10():1195-1206. PubMed ID: 37521029
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]